You are about to leave jnjmedtech.com. By clicking to continue, you will be taken to a web site governed by their own Legal and Privacy Policies.
TRUFILL™ n-BCA Liquid Embolic System
Create a customized SOLUTION
The TRUFILL™ n-BCA Liquid Embolic System is used under fluoroscopic guidance to obstruct or reduce blood flow to cerebral arteriovenous malformations (AVMs) via super-selective catheter delivery when pre-surgical devascularization is desired.
Lower Incidence of Microcatheter Retention
In a randomized, controlled trial, the catheter retention rate for TRUFILL® n‐BCA System of 1.6% (1/63) was lower than 9.3% (5/54) for ONYX™*
Significant Reduction in Fluoroscopy
In a comparative observational study, the mean total fluoroscopy time per patient of 65 (± 55) min with TruFill n-BCA was significantly shorter than 135 (± 65) min with Onyx (p < 0.0001)1
Lower Total Procedural Costs
TRUFILL™ n-BCA does not require the use of expensive detachable tip microcatheters or dual lumen balloon catheters
Related Products
PROWLER® microcatheter Family of Microcatheters
ENVOY
CERENOVUS Coil Portfolio
NEUROSCOUT® Steerable Guidewire
Specification
| Product Code | Kit Name | Contents |
|---|---|---|
| 631500 | TRUFILL™ n-BCA Liquid Embolic System 1 Gram Kit | One - 1 Gram TRUFILL™ n-BCA n-Butyl Cyanoacrylate, One - 10mL TRUFILL™ Ethiodized Oil, One - 1 Gram TRUFILL™ Tantalum Powder and One Self-piercing Cap. |
| 631400 | TRUFILL™ n-BCA Liquid Embolic System 2 Gram Kit | Contents: Two - 1 Gram TRUFILL™ n-BCA n-Butyl Cyanoacrylate, One - 10mL TRUFILL™ Ethiodized Oil, One - 1 Gram TRUFILL™ Tantalum Powder and Two Self-piercing Caps. |
References
* Loh Y, Duckwiler GR, Onyx Trial I (2010) A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. Clinical article. J Neurosurg 113 (4): 733-741.
- Velat GJ, Reavey-Cantwell JF, Sistrom C, Smullen D, Fautheree GL et al. (2008) Comparison of N-butyl cyanoacrylate and Onyx for the embolization of intracranial arteriovenous malformations: analysis of fluoroscopy and procedure times. Neurosurgery 63 (1 Suppl 1): ONS73-78; discussion ONS78-80.
196727-211123
Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, warnings and precautions.
Caution: US law restricts this device to sale by or on the order of a physician
This site is published by CERENOVUS which is solely responsible for its contents. It is intended for visitors from the United States.
© CERENOVUS 2022 Last Updated on 05/09/2022